¼¼°èÀÇ ¼öÇ÷ Áø´ÜÇÐ ½ÃÀå
Blood Transfusion Diagnostics
»óǰÄÚµå : 1655453
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 02¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 173 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,163,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,489,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°èÀÇ ¼öÇ÷ Áø´ÜÇÐ ½ÃÀåÀº 2030³â±îÁö 55¾ï ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2024³â¿¡ 42¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â ¼¼°èÀÇ ¼öÇ÷ Áø´ÜÇÐ ½ÃÀåÀº ºÐ¼® ±â°£ÀÎ 2024-2030³â¿¡ CAGR 4.7%·Î ¼ºÀåÇϸç, 2030³â¿¡´Â 55¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ ¸®Æ÷Æ®¿¡¼­ ºÐ¼®ÇÑ ºÎ¹®ÀÇ ÇϳªÀÎ ¼öÇ÷ Áø´Ü ±â±â´Â CAGR 4.4%¸¦ ±â·ÏÇϸç, ºÐ¼® ±â°£ Á¾·á±îÁö 17¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ¼öÇ÷ Áø´Ü ŰƮ & ½Ã¾à ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ Áß CAGR 4.9%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 11¾ï ´Þ·¯, Áß±¹Àº CAGR 7.1%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ ¼öÇ÷ Áø´ÜÇÐ ½ÃÀåÀº 2024³â¿¡ 11¾ï ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ÀÇ °æÁ¦´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 12¾ï ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³âÀÇ CAGRÀº 7.1%ÀÔ´Ï´Ù. ±âŸ ÁÖ¸ñÇØ¾ß ÇÒ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£ Áß CAGRÀº °¢°¢ 2.4%¿Í 4.4%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 2.8%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ ¼öÇ÷ Áø´ÜÇÐ ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

¼öÇ÷ Áø´ÜÇÐÀÌ ÇコÄɾ¼­ Á¡Á¡ ´õ Áß¿äÇØÁö´Â ÀÌÀ¯´Â ¹«¾ùÀΰ¡?

¼öÇ÷ Áø´ÜÇÐÀº ¸Å³â ¼ö¹é¸¸ ¸íÀÇ »ý¸íÀ» ±¸ÇÏ´Â ¼öÇ÷ÀÇ ¾ÈÀü¼º°ú À¯È¿¼ºÀ» º¸ÀåÇÏ´Â µ¥ ÇʼöÀûÀÔ´Ï´Ù. ¿Ü»ó, ¼ö¼ú ¹× ¸¸¼ºÁúȯ Áõ°¡·Î ¼öÇ÷¿¡ ´ëÇÑ ¼ö¿ä´Â Áö¼ÓÀûÀ¸·Î Áõ°¡Çϰí ÀÖÀ¸¸ç, ¼öÇ÷ °ü·Ã ÇÕº´ÁõÀ» ¿¹¹æÇϱâ À§ÇÑ ½Å·ÚÇÒ ¼ö ÀÖ´Â Áø´ÜÀÇ Çʿ伺ÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¼öÇ÷ Áø´ÜÇп¡¼­´Â Ç÷¾× »ùÇÃÀÇ ÀûÇÕ¼ºÀ» È®ÀÎÇϰí HIV, °£¿°, ¸»¶ó¸®¾Æ µî °¨¿°¼º ÁúȯÀ» ¼±º°Çϱâ À§ÇØ ¾ö°ÝÇÑ °Ë»ç¸¦ ½ÃÇàÇϰí ÀÖ½À´Ï´Ù. Àü ¼¼°è¿¡¼­ ¾ÈÀüÇÑ ¼öÇ÷¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÔ¿¡ µû¶ó ƯÈ÷ ¿Ü»óÀ̳ª ¼ö¼úÀÌ ¸¹Àº Áö¿ª¿¡¼­ ÀÌ·¯ÇÑ Áø´Ü ±â¼úÀº Àü ¼¼°è ÀÇ·á ½Ã½ºÅÛ¿¡¼­ ÇʼöÀûÀÎ ¿ä¼Ò·Î ÀÚ¸® Àâ°í ÀÖ½À´Ï´Ù.

±â¼ú Çõ½ÅÀº ¼öÇ÷ Áø´ÜÇÐÀÇ ¹Ì·¡¸¦ ¾î¶»°Ô Çü¼ºÇϰí Àִ°¡?

±â¼ú Çõ½ÅÀº ¼öÇ÷ Áø´ÜÇÐÀÇ ¹ßÀü¿¡ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖÀ¸¸ç, Á¤È®µµ¿Í È¿À²¼ºÀ» ¸ðµÎ Çâ»ó½Ã۰í ÀÖ½À´Ï´Ù. ÀÚµ¿È­µÈ Ç÷¾× °Ë»ç ±â¼úÀº °Ë»ç ÇÁ·Î¼¼½º¸¦ °£¼ÒÈ­Çϰí ÀÎÀû ¿À·ù¸¦ ÁÙÀ̸ç Áø´Ü ½Ã°£À» ´ÜÃàÇϰí ÀÖ½À´Ï´Ù. ÇÙ»êÁõÆø°Ë»ç(NAT)ÀÇ »ç¿ëÀº °¨¿°¼º Áúȯ °Ë»çÀÇ ¹Î°¨µµ¸¦ Å©°Ô Çâ»ó½ÃÄÑ Ç÷¾× ¸Å°³ º´¿øÃ¼¸¦ Á¶±â¿¡ ¹ß°ßÇÒ ¼ö ÀÖ°Ô Çß½À´Ï´Ù. ¶ÇÇÑ ºÐÀÚÁø´Ü ¹× Ç÷ûÇÐ ºÐ¾ßÀÇ Çõ½ÅÀº Ç÷¾×Çü °Ë»ç ¹× ÀûÇÕ¼º °Ë»çÀÇ Á¤È®¼ºÀ» ³ô¿© ¼öÇ÷¿¡ µû¸¥ À§ÇèÀ» ÃÖ¼ÒÈ­Çϰí ÀÖ½À´Ï´Ù. ¼öÇ÷ Áø´Ü¿¡ AI¸¦ ÅëÇÕÇÏ´Â °Íµµ ÁøÀüµÇ°í ÀÖÀ¸¸ç, ¸Ó½Å·¯´× ¾Ë°í¸®ÁòÀº Èñ±Í Ç÷¾×Çü°ú Ç×ü¸¦ ½Äº°ÇÏ´Â ¿¹Ãø ´É·ÂÀ» Çâ»ó½Ã۰í ÀÖ½À´Ï´Ù.

¼öÇ÷ Áø´ÜÇÐ ½ÃÀåÀÌ Á÷¸éÇÑ °úÁ¦´Â?

Áøº¸¿¡µµ ºÒ±¸ÇÏ°í ¼öÇ÷ Áø´Ü ½ÃÀåÀº ±ÔÁ¦ À庮, ³ôÀº ºñ¿ë, ÷´Ü ÀÎÇÁ¶ó ÇÊ¿ä µî ¿©·¯ °¡Áö ¹®Á¦¿¡ Á÷¸éÇØ ÀÖ½À´Ï´Ù. ƯÈ÷ ½ÅÈï ±¹°¡¿¡¼­´Â Áø´Ü °Ë»çÀÇ ¾ÈÀü¼º°ú À¯È¿¼ºÀ» °ü¸®ÇÏ´Â ±ÔÁ¦°¡ ¾ö°ÝÇÏ¿© ½Å±â¼úÀÇ ½ÂÀΰú ½ÃÀå °³Ã´À» Áö¿¬½Ãų ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ Ã·´Ü Ç÷¾× °Ë»ç ±â¼úÀ» µµÀÔÇÏ´Â µ¥ µå´Â ºñ¿ëÀº ƯÈ÷ ÀÚ¿øÀÌ ºÎÁ·ÇÑ È¯°æ¿¡¼­ º´¿ø ¹× Ŭ¸®´Ð¿¡ ¾öû³­ ºñ¿ëÀÌ ¼Ò¿äµÉ ¼ö ÀÖ½À´Ï´Ù. Áø´Ü ÀÎÇÁ¶ó¿¡ ´ëÇÑ Á¢±Ù¼ºÀÌ Á¦ÇÑÀûÀÎ Áö¿ª¿¡¼­´Â ÀÚµ¿È­ ¹× ¼÷·ÃµÈ Àü¹®°¡ ºÎÁ·À¸·Î ÀÎÇØ ÃֽмöÇ÷ Áø´ÜÀ» µµÀÔÇÏ´Â µ¥ ¾î·Á¿òÀ» °ÞÀ» ¼ö ÀÖ½À´Ï´Ù. ±×·¯³ª À̵é Áö¿ª¿¡¼­´Â ÀÇ·á ½Ã½ºÅÛÀ» °­È­Çϰí Áø´Ü ¼­ºñ½º¿¡ ´ëÇÑ Á¢±Ù¼ºÀ» È®´ëÇϱâ À§ÇÑ ³ë·ÂÀÌ ÁøÇàµÇ°í ÀÖÀ¸¸ç, ÀÌ·¯ÇÑ À庮Àº Á¡Â÷ ¿ÏÈ­µÇ°í ÀÖ½À´Ï´Ù.

¼öÇ÷ Áø´ÜÇÐ ½ÃÀåÀÇ ¼ºÀåÀº ¸î °¡Áö ¿äÀο¡ ÀÇÇØ ÃËÁø

¼öÇ÷ Áø´Ü ½ÃÀåÀÇ ¼ºÀåÀº ¾ÈÀüÇÑ ¼öÇ÷¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡, ±â¼ú Çõ½Å, ½ÅÈï ½ÃÀå¿¡¼­ ¼ö¿ä Áõ°¡ µî ¿©·¯ ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. ¼ö¼ú °Ç¼ö, ¿Ü»ó °Ç¼ö, ¾Ï ¹× Ç÷¾× Áúȯ µîÀÇ Ä¡·á °Ç¼ö Áõ°¡´Â Á¤È®ÇÑ Ç÷¾× °Ë»ç¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ÀÚµ¿È­µÈ °Ë»ç Ç÷§Æû°ú ºÐÀÚÁø´Ü°ú °°Àº ±â¼úÀÇ ¹ßÀüÀ¸·Î °Ë»ç °úÁ¤ÀÌ ´õ¿í ½Å¼ÓÇÏ°í ½Å·ÚÇÒ ¼ö ÀÖ°Ô µÊ¿¡ µû¶ó ½ÃÀå ¼ºÀå¿¡ ´õ¿í ¹ÚÂ÷¸¦ °¡Çϰí ÀÖ½À´Ï´Ù. ½ÅÈï °æÁ¦±¹µéÀÇ ÀÇ·á ÁöÃâ°ú ÀÎÇÁ¶ó ±¸ÃàÀÌ Áõ°¡Çϸ鼭 ¼öÇ÷ Áø´ÜÇÐ ½ÃÀåÀÇ ¼ºÀå ±âȸ¸¦ âÃâÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ¾ÈÀüÇÑ ¼öÇ÷À» Àå·ÁÇÏ´Â Á¤ºÎÀÇ ±¸»ó°ú ÀÎ½Ä °³¼± Ä·ÆäÀεµ ½ÃÀåÀÇ ¹ßÀüÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

ºÎ¹®

¿ëµµ(Ç÷¾×Çü ºÐ·ù, Áúº´ °Ë»ç);&ÃÖÁ¾ ¿ëµµ(º´¿ø, Ç÷¾×ÀºÇà, Áø´Ü ½ÇÇè½Ç, Ç÷Àå ºÐȹ ±â¾÷);&Á¦Ç° À¯Çü(±â±â, ŰƮ, ½Ã¾à)

Á¶»ç ´ë»ó ±â¾÷ÀÇ ¿¹(ÁÖ¸ñ 42»ç)

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå °³¿ä

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Blood Transfusion Diagnostics Market to Reach US$5.5 Billion by 2030

The global market for Blood Transfusion Diagnostics estimated at US$4.2 Billion in the year 2024, is expected to reach US$5.5 Billion by 2030, growing at a CAGR of 4.7% over the analysis period 2024-2030. Blood Transfusion Diagnostic Instruments, one of the segments analyzed in the report, is expected to record a 4.4% CAGR and reach US$1.7 Billion by the end of the analysis period. Growth in the Blood Transfusion Diagnostic Kits & Reagents segment is estimated at 4.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.1 Billion While China is Forecast to Grow at 7.1% CAGR

The Blood Transfusion Diagnostics market in the U.S. is estimated at US$1.1 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.2 Billion by the year 2030 trailing a CAGR of 7.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.4% and 4.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.8% CAGR.

Global Blood Transfusion Diagnostics Market - Key Trends & Drivers Summarized

Why Is Blood Transfusion Diagnostics Gaining Importance in Healthcare?

Blood transfusion diagnostics are critical to ensuring the safety and effectiveness of blood transfusions, a procedure that saves millions of lives annually. With rising incidences of trauma, surgeries, and chronic diseases, the demand for blood transfusions continues to grow, driving the need for reliable diagnostics to prevent transfusion-related complications. Blood transfusion diagnostics involve rigorous testing of blood samples to ensure compatibility and screen for infectious diseases like HIV, hepatitis, and malaria. As the demand for safe transfusions increases globally, particularly in regions with high rates of trauma and surgery, these diagnostic technologies are becoming essential in healthcare systems worldwide.

How Are Technological Innovations Shaping the Future of Blood Transfusion Diagnostics?

Technological innovations are playing a key role in advancing blood transfusion diagnostics, improving both accuracy and efficiency. Automated blood screening technologies have streamlined the testing process, reducing human error and speeding up diagnosis times. The use of nucleic acid amplification tests (NAT) has significantly improved the sensitivity of infectious disease screening, enabling earlier detection of blood-borne pathogens. Moreover, innovations in molecular diagnostics and serology have enhanced the precision of blood typing and compatibility testing, minimizing the risks associated with transfusions. The integration of AI in transfusion diagnostics is also emerging, with machine learning algorithms enhancing predictive capabilities for identifying rare blood types and antibodies.

What Challenges Does the Blood Transfusion Diagnostics Market Face?

Despite the advancements, the blood transfusion diagnostics market faces several challenges, including regulatory hurdles, high costs, and the need for advanced infrastructure. Strict regulations governing the safety and efficacy of diagnostic tests, particularly in developed countries, can delay the approval and market entry of new technologies. Additionally, the cost of implementing advanced blood screening technologies can be prohibitive for hospitals and clinics, particularly in low-resource settings. In regions with limited access to diagnostic infrastructure, the lack of automation and skilled professionals can hinder the adoption of modern transfusion diagnostics. However, initiatives to strengthen healthcare systems and expand access to diagnostic services in these regions are slowly mitigating these barriers.

The Growth in the Blood Transfusion Diagnostics Market Is Driven by Several Factors

The growth in the blood transfusion diagnostics market is driven by several factors, including the increasing need for safe blood transfusions, technological innovations, and rising demand in emerging markets. The growing number of surgeries, trauma cases, and treatments for conditions such as cancer and blood disorders contribute to the heightened demand for accurate blood testing. Technological advancements, such as automated testing platforms and molecular diagnostics, are making the screening process faster and more reliable, further boosting market growth. Emerging economies are witnessing an increase in healthcare spending and infrastructure development, creating opportunities for the expansion of blood transfusion diagnostics. Furthermore, government initiatives and awareness campaigns promoting safe transfusion practices are also helping to drive the market forward.

SCOPE OF STUDY:

The report analyzes the Blood Transfusion Diagnostics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Application (Blood Grouping, Disease Screening); End-Use (Hospitals, Blood Banks, Diagnostic Laboratories, Plasma Fractionation Companies); Product Type (Instruments, Kits & Reagents)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â